What Is Werewolf Therapeutics, Inc. (HOWL) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Werewolf Therapeutics, Inc.'s intrinsic value is estimated at $0.57, suggesting a +68.1% average upside from the current price of $0.34. While 4 models see room for appreciation, model agreement is not unanimous as 3 models flag potential overvaluation. Model dispersion is worth noting: Dynamic NAV targets $1.64 (+382.8%), versus ML-RIV at $0.05 (-86.4%). This +469.2% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About HOWL?
7 of 13 models are currently active for HOWL. Of these, 4 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates HOWL's intrinsic value at $0.17, implying -49.8% downside from the current price. See which stocks rank higher →
How Does HOWL Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, HOWL ranks #340 by Quality of Company score. CirclFi's QOC score of 3.9/10 evaluates 32 fundamental signals. A score of 3.9 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Werewolf Therapeutics, Inc.'s positioning within the Pharmaceutical Preparations segment means that FDA approval probability plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.
Is HOWL a Value Trap?
CirclFi's Value Trap algorithm assigns HOWL a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Werewolf Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Werewolf Therapeutics, Inc. earns a quality score of 3.9/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +469.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every HOWL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across HOWL's 7 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad